ID

6181

Beskrivning

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Länk

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Nyckelord

Versioner (4)
  1. 2011-11-14 2011-11-14 -
  2. 2013-12-06 2013-12-06 - Martin Dugas
  3. 2014-04-11 2014-04-11 - Julian Varghese
  4. 2014-12-16 2014-12-16 - Martin Dugas
Uppladdad den

16 december 2014

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility AZD1152 and LDAC in AML

Engelsk

Eligibility AZD1152 and LDAC in AML

1 Formulär  
Inclusion criteria
Beskrivning

Inclusion criteria

Alias
UMLS CUI-1
C1512693
Provision of written informed consent
Beskrivning

consent

Datatyp

boolean

Alias
UMLS CUI-1
C0021430
Newly diagnosed male or female patients aged 60 and over
Beskrivning

Newly diagnosed patients aged 60 and over

Datatyp

boolean

Alias
UMLS CUI-1
C0001779
De Novo or Secondary AML
Beskrivning

De Novo or Secondary AML

Datatyp

boolean

Alias
UMLS CUI-1
C0023467
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Beskrivning

Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia

Datatyp

boolean

Alias
UMLS CUI-1
C3242266
UMLS CUI-2
C0600558
Exclusion criteria
Beskrivning

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Beskrivning

Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product

Datatyp

boolean

Alias
UMLS CUI-1
C2348568
Administration of LDAC is clinically contraindicated
Beskrivning

Administration of LDAC is clinically contraindicated

Datatyp

boolean

Alias
UMLS CUI-1
C1301624
UMLS CUI-2
C0010711
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Beskrivning

Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)

Datatyp

boolean

Alias
UMLS CUI-1
C0023487
Patients with blast crisis of chronic myeloid leukaemia
Beskrivning

Patients with blast crisis of chronic myeloid leukaemia

Datatyp

boolean

Alias
UMLS CUI-1
C0023473
UMLS CUI-2
C0005699
Tillbaka till toppen

Similar models

Eligibility AZD1152 and LDAC in AML

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
consent
Item
Provision of written informed consent
boolean
C0021430 (UMLS CUI-1)
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779 (UMLS CUI-1)
AML
Item
De Novo or Secondary AML
boolean
C0023467 (UMLS CUI-1)
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266 (UMLS CUI-1)
C0600558 (UMLS CUI-2)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568 (UMLS CUI-1)
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624 (UMLS CUI-1)
C0010711 (UMLS CUI-2)
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487 (UMLS CUI-1)
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473 (UMLS CUI-1)
C0005699 (UMLS CUI-2)
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial